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Abstract
Antitumor functions of the host immune system are frequently compromised in patientswithmalignancies. In the current
study, we evaluated the relationship between expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the pro-
apoptotic protein Bax (the Bcl-2/Bax ratio) in peripheral blood mononuclear cells and clinical outcomes in patients with
head and neck carcinomas. The overall survival (OS) time of patients with Bcl-2/Bax ratios≥ 1.2 tended to be longer than
that of patients with Bcl-2/Bax ratios < 1.2 but not significantly so (P = .084, n = 61). Disease-free survival (DFS) of
patients with Bcl-2/Bax ratios ≥ 1.2 was statistically significantly longer than that of patients with Bcl-2/Bax ratios <
1.2 (P= .001, n= 76). All of the patients whose Bcl-2/Bax ratio is≥ 2.0 were alive after 36 months and survived without
any evidence of disease for 24months (Bcl-2/Bax≥ 2.0 versusBcl-2/Bax<2.0; P= .035, n=61 inOS,P< .001, n=76 in
DFS, respectively). In 56 patients who received immunochemoradiotherapy using UFT and OK-432 in combination with
radiotherapy, a statistically significant relationship between the Bcl-2/Bax ratio and the therapeutic effect estimated using
Response Evaluation Criteria in Solid Tumors was observed, as well as a relation with interferon-γ (IFN-γ) induction in
response to the therapy [P = .002 in complete response versus partial response + stable disease; P = .046 in IFN-γ(+)
versus IFN-γ(−)]. In addition, therewere significant correlations of theBcl-2/Bax ratiowith both the absolute number of CD4+
T cells and the rate of CD4+ T cell and natural killer cell activity. These findings strongly suggest that the balance of ex-
pression of Bcl-2 and Bax genes in circulating immune cells has a high prognostic value in head and neck cancer patients.
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Introduction
Numerous investigators have reported that the decreased function of
the immune system might be closely involved in the growth and
metastasis of head and neck carcinoma (HNC) cells. Although a sat-
isfactory immune status might be critical in the success of cancer
treatments, such as surgery, radiotherapy, and chemotherapy, as well
as immunotherapy, and in obtaining a favorable clinical outcome,
antitumor functions of the host immune system are frequently com-
promised in patients with malignancies including HNC. It has been
reported that HNC cells might escape from the immune surveillance
by evading immune cell recognition and by inhibiting directly host
immune function. Mechanisms of immune evasion by HNC cells
include modulation of tumor antigen expression and downregulating
expression of surface major histocompatibility complex class I mole-
cules. In addition, HNC cells can directly inhibit the antitumor host
responses through production of immune-suppressive soluble factors,
such as transforming growth factor–β, prostaglandins, and Fas ligand,
and through induction of immune inhibitory cells including regula-
tory T cells and myeloid-derived suppressor cells in the tumor micro-
environment [1–4]. In vitro experiments involving co-incubation
of activated T lymphocytes with tumor cells have shown that both
receptor-mediated and mitochondrial pathways mediate tumor-
induced apoptosis of T cells [5]. Kim et al. demonstrated that expres-
sion ratio of Bax and Bcl-2 proteins (Bax/Bcl-2 ratio), which was
measured by quantitative flow cytometry, was elevated in circulating
CD8+ T cells from patients with head and neck squamous cell car-
cinomas (HNSCCs) and that patient-derived CD8+ T cells appeared
to be sensitive to apoptosis as compared with those from healthy
donors [6]. In addition, it has been reported that Bcl-2 family pro-
teins such as antiapoptotic proteins Bcl-2 and Bcl-xL, as well as the
apoptotic protein Bax, play significant roles in survival and prolifer-
ation of many types of lymphocytes including CD4+ T cells [7],
CD19+ B cells [8], natural killer (NK) cells [9], and γδT cells [10]
and also showed that Bcl-2 protein is an important factor for survival
of naive T cells as well as for development of memory T cells [7,11].
In mammalian cells, mitochondria have a central role in apoptosis
that is regulated by members of the Bcl-2 family [12]. Many inves-
tigators have demonstrated that Bcl-2 family proteins play a significant
role for survival of cancer cells and that expression of these proteins in
cancer cells may be diagnostic and prognostic biomarker(s) in pa-
tients with many types of malignancies. In patients with HNSCC,
Homma et al. reported that Bcl-2 positivity is associated with better
locoregional control [13], while Gallo et al. reported that Bcl-2 ex-
pression is closely associated with a high risk of recurrence and poor
survival in stage I and II HNSCC patients [14]; however, Bcl-2 expres-
sion in cancer cells has not yet been established as a prognostic bio-
marker. Bcl-2 family proteins also play a significant role for survival
and functions of immune cells [7–11], and as described above, the
host immune system plays a critical role in the success of cancer
therapy. Therefore, various immune parameters such as serum cyto-
kine levels, subset analysis of circulating lymphocytes, and profiles of
infiltrating immune cells in the tumor microenvironment have been
assessed as biomarkers, whereas no immunologic parameter has yet
entered routine clinical reporting [15–17].
In the current study, we analyzed the expressions of Bcl-2 and Bax
mRNAs in circulating immune cells derived from patients with HNC
and assessed their prognostic values. This is the first report demon-
strating that evaluation of mRNAs for proapoptotic and antiapoptotic
proteins in circulating immune cells can play a role in prognosis.
Materials and Methods
Patients and Treatment Protocol
This study was carried out in accordance with the standards of our
Institutional Committee for the Protection of Human Subjects. In-
formed written consent was obtained from all patients, and the collec-
tion of the samples was approved by the Institutional Review Board.
From 1988 to 2006, 79 HNC patients (44 males and 35 females)
who were treated at the Second Department of Oral and Maxillofacial
Surgery, Tokushima University Hospital were enrolled in this study.
The median patient age was 60.9 years (range, 22–90 years). On the
basis of the tumor-node-metastasis (TNM) system for the classification
of malignant diseases, there were 8 T1 cancers, 41 T2 cancers, 19 T3
cancers, 8 T4 cancers, 44 N0 cancers, 23 N1 cancers, 11 N2 cancers,
and 1 N3 cancer. All cancers were M0. Seventy-five patients were
histopathologically diagnosed with squamous cell carcinomas, two with
adenoid cystic carcinomas and two with mucoepidermoid carcinomas.
Primary sites of the tumors included the tongue (n = 30), lower gingiva
(n = 21), upper gingiva (n = 10), hard palate (n = 5), floor of the mouth
(n = 4), buccal mucosa (n = 4), oropharynx (n = 2), submandibular
gland (n = 2), and lip (n = 1).
Of 79 patients, 59 received chemotherapy [UFT, an oral fluoro-
pyrimidine formulation combining tegaful and uracil in a 1:4 ratio
(Taiho Pharmaceutical Co, Tokyo, Japan), or S-1, an oral fluoropyrimi-
dine formulation combining tegaful, gimeracil, and oteracil potassium
in a 1:0.4:1 ratio (Taiho Pharmaceutical Co)] and immunotherapy
(OK-432, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan) in com-
bination with radiation therapy (a total irradiation dose of 50 to
60 Gy) as a first-line treatment. OK-432, which is a penicillin-killed
and lyophilized preparation of a low-virulence strain (Su) of Strepto-
coccus pyogenes (group A), is being successfully used as an immuno-
therapeutic agent in many types of malignancies [18,19]. OK-432
was administered peritumorally or intradermally at a dose of 0.5
Klinische Einheit, i.e., 50 μg/week. When any severe adverse events
were not shown, the dose was increased up to 5 Klinische Einheit/
week, and OK-432 administration was continued until the 6th month
after visible tumor(s) disappeared or surgically removed. Patients were
monitored for general symptoms related to OK-432 therapy, such as
increased fever and/or fatigue. The flowchart diagram describing the
treatment of the patients is shown in Figure 1A. The tumor responses
to the combination therapy were evaluated as complete response (CR),
partial response (PR), stable disease (SD), and progressive disease (PD)
according to the Response Evaluation Criteria in Solid Tumors. Ad-
verse events were evaluated by grading toxicity according to the Na-
tional Cancer Institute Common Terminology Criteria for Adverse
Events guidelines, version 3.0. Eight patients had surgery followed by
chemotherapy or by chemoradiotherapy, and five patients received
only surgery.
Sample Collection
Before any treatments, peripheral blood mononuclear cells
(PBMCs) were prepared by the standard Ficoll-Hypaque gradi-
ent density centrifugation method [20]. Sera were also collected
5 hours before and 18 hours after OK-432 administration and
immediately frozen at −80°C until assayed for interferon-γ (IFN-γ).
IFN-γ levels were analyzed by ELISA in SRL Inc (Tokyo, Japan), which
is the company receiving the orders of cytokine assay in Tokyo, Japan.
The ELISA system has a lower limit of sensitivity of 7.8 pg/ml for de-
tecting human IFN-γ.
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RNA Extraction and Semiquantitative Reverse
Transcription–Polymerase Chain Reaction
Total RNAs were extracted from human PBMCs by a modified
acid guanidinium thiocyanate–phenol–chloroform using ISOGEN
RNA extracting mixture (Nippon Gene, Toyama, Japan) according
to the manufacturer’s recommendations. Expression of mRNAs for
Bcl-2, Bax, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a
housekeeping gene that was used as an internal control, was detected
by semiquantitative reverse transcription–polymerase chain reaction
(RT-PCR). First, 1 μg of total RNA was reverse-transcribed using
Moloney murine leukemia virus reverse transcriptase and random
primers (Life Technologies Inc, Rockville, MD) in a volume of
20 μl at 42°C for 60 minutes by following the manufacturer’s
instructions. Next, 2 μl of the reverse-transcribed mixture was sub-
jected to PCR [10 mM Tris-HCl (pH 8.3); 50 mM KCl; 1.5 mM
MgCl2; 0.01% gelatin; dATP, dGTP, dTTP, and dCTP, each at
20 mM], 0.5 U of Taq polymerase (TaKaRa Bio Inc, Otsu, Japan),
and 0.25 pmol of each primer in a total volume of 20 μl. This study
used 5′-GTGGAGGAGCTCTTCAGGGA-3′ as an upstream primer
and 5′-AGGCACCCAGGGTGAGCAA-3′ as a downstream primer
for Bcl-2, which yielded a 304-bp fragment; 5′-GGCCCACCAG-
CTCTGAGCAGA-3′ as an upstream primer and 5′-GCCACGTG-
GGCGGTCCCAAAGT-3′ as a downstream primer for Bax, which
yielded a 479-bp fragment [21]; and 5′-GAAATCCCAGCACCATC-
TTCCCAGG-3′ as an upstream primer and 5′-GTGGTGGACCT-
CATGGCCCACCATG-3′ as a downstream primer for GAPDH,
which yielded a 781-bp fragment [22]. To amplify the fragments,
25, 28, or 30 PCR cycles were used, with each cycle consisting of
94°C for 60 seconds, 55°C for 90 seconds, and 72°C for 150 seconds,
with an initial denaturation step of 94°C for 5 minutes and a final
elongation step of 72°C for 5 minutes. PCR was carried out in a
DNA Thermal Cycler (TaKaRa Bio Inc). The amplified PCR product
Figure 1. (A) Flowchart diagram of the treatment of the patients. (B) Expression of Bcl-2 and BaxmRNAs in PBMCs derived from patients
with head and neck cancer. Total RNAswere isolated from PBMCs from head and neck cancer patients and were assayed for expression of
Bcl-2, Bax, and GAPDHmRNAs using semiquantitative RT-PCR analysis. Data are representative of at least three independent experiments.
(C) Differences of Bcl-2/Bax ratio in head and neck cancer patients and healthy volunteers.
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was electrophoresed through 1.5% agarose gels containing 100 ng/ml
ethidium bromide. After electrophoresis, gels were illuminated with
UV light, viewed, and photographed (Polaroid type 667 film; Polaroid
Corp, Cambridge, MA). Densitometric analysis for the RT-PCR band
patterns was done using NIH Image 1.59 software (National Insti-
tutes of Health, Bethesda, MD). Expression values of Bcl-2 and
Bax mRNAs were represented as ratios to the density of GAPDH.
The identification of each amplified product was confirmed by
automated DNA sequencing.
Assay for NK and Lymphokine-Activated Killer Cell Activities
The cytotoxic activities of human PBMCs were assayed against
K-562, a markedly sensitive target for human NK cells, and Daudi,
a sensitive target for human lymphokine-activated killer (LAK) cells
but not destroyed by human NK cells, in a 51Cr release test. For mea-
suring pre-LAK activity, PBMCs derived from patients were cultured
with 1000 IU/ml recombinant interleukin-2 (Primmune Inc, Kobe,
Japan) for 72 hours before the analysis as described by Aramaki et al.
[23]. The 51Cr release was carried out as described previously [24]. For
cell-mediated cytotoxicity assays, 4.0 × 105 effector cells were mixed in
the wells of 96-well microtiter plates (Falcon; Becton Dickinson
Labware, Lincoln Park, NJ) with 1.0 × 104 51Cr-labeled target cells
(effector cell/target cell, 40:1) in a total volume of 200 μl of medium
and incubated at 37°C for 4 hours. The percent specific 51Cr release
was calculated according to the formula: [(E − S )/(M − S )] × 100,
where E is the experimental 51Cr release, S is the spontaneous 51Cr
release, andM is the maximum 51Cr release. Spontaneous 51Cr release
was determined by incubation of target cells without effector cells
and maximal 51Cr release was determined by adding 100 μl of NP-
40 (Sigma, Deisenhofen, Germany) to labeled target cells. The
percent specific 51Cr release was considered as the NK, LAK, or
pre-LAK activity.
Flow Cytometric Analysis of Cell Surface Antigens
Cell surface staining was performed using the following mouse
anti-human monoclonal antibodies. The antibodies to CD3 (clone
SK7), CD4 (clone SK3), CD8 (clone SK1), CD16 (clone B73.1),
and CD57 (clone HNK-1) were purchased from Pharmingen (San
Diego, CA). Isotype-matched control mouse IgGs conjugated with
fluorescein isothiocyanate were also purchased from Pharmingen.
All monoclonal antibodies were directly labeled with either fluores-
cein isothiocyanate or phycoerythrin. The cells were resuspended in
phosphate-buffered saline containing 0.1% sodium azide and 0.2%
BSA and then were incubated for 30 minutes at 4°C with a saturating
concentration of each monoclonal antibody according to the manu-
facturer’s instructions. After the cells were washed twice, their fluo-
rescence intensity was determined using a flow cytometer (EPICS
XL-MCL; Beckman Coulter, Fullerton, CA).
Statistical Analysis
The relationships between Bcl-2/Bax, Bcl-2/GAPDH, and Bax/
GAPDH ratios and sex, TNM classification, IFN-γ induction, prog-
nosis, as well as therapeutic effect were performed by using Student’s
two-tailed t test. Correlations between Bcl-2/Bax, Bcl-2/GAPDH,
and Bax/GAPDH ratios and immunologic parameters and age were
quantified by Spearman’s rank correlation coefficient and regression
calculation. Kaplan-Meier curves and log-rank tests were used to assess
differences in survival time between the groups. P < .05 were considered
statistically significant.
Results
Expression of Bcl-2 and Bax mRNAs in PBMCs Derived
from HNC Patients and from Healthy Donors
We examined the expression of Bcl-2 and Bax mRNAs by semi-
quantitative RT-PCR analysis. Representative data of four patients
are shown in Figure 1B. PBMCs from patient 2 highly expressed both
Bcl-2 and Bax mRNAs; thus, the Bcl-2/Bax ratio was medium (1.27).
Expression of both Bcl-2 and BaxmRNAs was only faint in those from
patient 15, for whom the Bcl-2/Bax ratio was also medium (0.80). In
patient 16, only slight expression of Bcl-2 mRNA and high expression
of Bax mRNA were observed; hence, the Bcl-2/Bax ratio was low
(0.25). In patient 40, Bcl-2 expression was high and Bax was low, so
the Bcl-2/Bax ratio was high (4.43).
Next, we compared the Bcl-2/Bax ratio in the PBMCs derived from
the head and neck cancer patients (n = 79) with that from healthy
volunteers (n = 15). Although the Bcl-2/Bax ratios in the patients
(1.475 ± 1.028; median value, 1.197) tended to be lower than those
in healthy donors (1.864 ± 1.285; median value, 1.452), no statistically
significant difference was shown (P = .201; Figure 1C ).
No statistically significant relationship was observed between Bcl-
2/Bax, Bcl-2/GAPDH, and Bax/GAPDH ratios and sex (P = .185, P =
.350, and P = .985, respectively) or age (P = .866, P = .744, and P =
.806, respectively). In addition, no statistical relationship between
Bcl-2/Bax, Bcl-2/GAPDH, and Bax/GAPDH ratios and T stage [P =
.233, P = .774, and P = .869, respectively in early state (T1 + T2)
versus advanced state (T3 + T4)] or N stage [P = .324, P = .609,
and P = .130, respectively in N(−) versus N(+)] was seen (Table W1).
Relationship between Expression of Bcl-2 and
Bax mRNAs and Clinical Outcome
We assessed the prognostic significance of expression of Bcl-2 and
Bax mRNAs in PBMCs derived from patients with HNC.
First, we evaluated the relationship between Bcl-2/Bax ratio and
survival time. Overall survival (OS) was examined for the association
with Bcl-2/Bax ratio in the 61 patients who could be followed up at
least 36 months after the initial diagnosis (Figure 2). Because the
median value of Bcl-2/Bax ratio in all 79 patients tested in the cur-
rent study was 1.197, we have chosen 1.2 as a cutoff point. When
the cutoff level was set to 1.2, patients who showed Bcl-2/Bax ratio ≥
1.2 survived longer than the patients who showed a Bcl-2/Bax ratio <
1.2, but this difference between the two groups was not statistically
significant (P = .0838; Figure 2A). When the cutoff level was set to
2.0, the survival time of the patients who showed high Bcl-2/Bax
ratios was statistically longer than that of the patients with lower
Bcl-2/Bax ratios (P = .035). All of the patients with Bcl-2/Bax ratio ≥
2.0 have been alive over 36 months (Figure 2B). The relationship
between Bcl-2/Bax ratio and disease-free survival (DFS) was also as-
sessed in 76 patients whose long-term outcome (≥24 months after
first treatment) was known. The DFS of the patients whose tumor(s)
could not be completely cured by surgery, radiotherapy, chemotherapy,
and/or immunotherapy was 0 month. When the cutoff level was set
to 1.2, the DFS of patients with Bcl-2/Bax ratios ≥ 1.2 was signifi-
cantly longer than that of patients with Bcl-2/Bax ratios < 1.2 (P =
.001; Figure 2C). When the cutoff level was set to 2.0, the patients
with Bcl-2/Bax ratios ≥ 2.0 survived much longer than the patients
with Bcl-2/Bax ratios < 2.0 (P = .0005), and all patients with Bcl-2/
Bax ratios ≥ 2.0 have been alive in disease-free condition for over
24 months (Figure 2D).
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In the current cases, disease progression that is expressed with
TNM classification was related to the duration of the survival (data
not shown), similar to the results reported previously by numerous
different investigators; however, disease progression and the Bcl-2/
Bax ratio do not necessarily correlate with each other, as described
above (Table W1). Namely, although the 15 patients with Bcl-2/
Bax ratios ≥ 2 (Figure 2B) included six patients (40%) with ad-
vanced cancer, the 3-year survival was 100%. In DFS, 16 patients
with Bcl-2/Bax ratios ≥ 2 (Figure 2D) included 7 (43.8%) with ad-
vanced cancer, while all of the 16 patients showed no evidence of
disease (NED) at 24 months from completion of the first treatment
(Figure 2 and data not shown). Furthermore, 76 patients who could
be followed up for at least 24 months after the first treatment
consisted of 39 patients (51.3%) with Bcl-2/Bax ratios ≥ 1.2 and
37 patients (48.7%) with Bcl-2/Bax ratios < 1.2 (Figure 2C ). Of
the 39 patients who showed Bcl-2/Bax ratios ≥ 1.2, 18 early-stage
(T1 + T2; 46.2%) and 21 advanced-stage (T3 + T4) patients
(53.8%) were included. The 37 patients with Bcl-2/Bax ratios < 1.2
consisted of 17 early-stage (45.9%) and 20 advanced-stage patients
(54.1%). Although no significant difference was observed in the rates
of early stage and advanced stage between Bcl-2/Bax ratio ≥ 1.2 and
Bcl-2/Bax ratio < 1.2 patients (data not shown), the two-year DFS rate
of Bcl-2/Bax ratio ≥ 1.2 group [76.9% (30 of 39 patients)] was statis-
tically significantly higher than that of the Bcl-2/Bax ratio < 1.2 group
[43.2% (16 of 37 patients)] (P = .001; Figure 2 and data not shown).
Next, we compared the Bcl-2/Bax ratio in PBMCs from patients
who were alive and from patients who were dead at 36 months from
initial diagnosis. A significant difference in the Bcl-2/Bax ratios of the
two groups was observed (P = .027; Figure 3A). Furthermore, there was
a statistically significant difference in the Bcl-2/Bax ratios of patients
with NED at 24 months and in patients with active disease (AD) at
24 months from first treatments (P = .010; Figure 3B). The Bcl-2
and Bax expression values, as represented by Bcl-2/GAPDH and Bax/
GAPDH ratios, showed no significant difference within these group
pairings (alive vs dead, NED vs AD), but there was a tendency for
higher Bcl-2 expression values in alive and NED groups than in the
dead and AD groups (P = .076 and P = .063, respectively; Figure 3,
A and B).
We next examined the therapeutic effects in association with
expression of Bcl-2 and Bax mRNAs in 56 patients who received
immunochemoradiotherapy using OK-432 and UFT or S-1, in com-
bination with radiation. The Bcl-2/Bax ratio as well as Bcl-2
expression value in patients who showed CR was significantly high
compared with those in patients who showed PR and SD (P = .002
Figure 2. Prognostic value of Bcl-2/Bax ratio. Kaplan-Meier estimates of (A and B) OS and (C and D) DFS. Differences (A and C) of Bcl-2/
Bax ratio≥ 1.2 (solid line) versus Bcl-2/Bax ratio < 1.2 (dotted line) and (B and D) of Bcl-2/Bax ratio≥ 2.0 (solid line) versus Bcl-2/Bax ratio <
2.0 (dotted line) were calculated by log-rank test. Asterisk denotes P < .05, indicating statistical significance.
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and P = .012, respectively; Figure 3C ). The Bax expression
value showed no significant association with the clinical response
(P = .688).
The immunotherapeutic effect was also evaluated in the association
with Bcl-2/Bax expression. We analyzed serum IFN-γ levels in patients
5 hours before and 18 hours after OK-432 administration. Serum
IFN-γ protein was not detectable in any of the patients before OK-
432 treatment (data not shown). Eighteen hours after OK-432 injec-
tion, IFN-γ protein levels in the sera were detectable in 36 patients
(64.3%) and were still not detectable in 20 patients (35.7%). Patients
whose serum IFN-γ became detectable in response to the therapy were
determined IFN-γ(+). The Bcl-2/Bax ratio but not the Bcl-2 or Bax
expression value was significantly higher in IFN-γ(+) patients than
IFN-γ(−) patients (P = .046; Figure 3D).
Differences between Primary Sites
Next, we have examined the difference in Bcl-2/Bax ratio and in
clinical outcome among the different primary sites such as tongue
and gingiva that have enough number of cases for analysis. Squamous
cell carcinoma of hard palate has been included in upper gingiva. A
case of adenoid cystic carcinoma in tongue has been excluded from
the analysis. There was no significant difference in Bcl-2/Bax ratio be-
tween tongue and upper gingiva, between tongue and lower gingiva,
between upper and lower gingiva, as well as between tongue and
gingiva (upper gingiva + lower gingiva; P = .597, 0.797, 0.838, and
0.542, respectively; Figure 4A). Interestingly, although tongue cancer
patients who showed Bcl-2/Bax ratio ≥ 1.2 tended to survive longer
than those who showed a Bcl-2/Bax ratio < 1.2 (P = .063), no ten-
dency of the difference was observed between Bcl-2/Bax ratio high
Figure 3. Differences of Bcl-2/Bax ratio, Bcl-2 expression, and Bax expression in (A) alive and dead patients, (B) NED and AD patients,
(C) CR and PR + SD patients, and (D) IFN-γ(+) and IFN-γ(−) patients were analyzed by Student’s two-tailed t test. Asterisk denotes P< .05,
indicating statistical significance.
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group and low group in the patients with gingival cancer (P = .540;
Figure 4B). In DFS, a statistically significant difference was observed
between high and low groups in Bcl-2/Bax ratio in the patients with
tongue cancer (P = .012) but not in those with gingival cancer (P =
.117; Figure 4C ). However, in clinical response, the Bcl-2/Bax ratio in
patients who showed CR were significantly high compared with those
in patients who showed PR and SD both in tongue cancer patients
and in gingival cancer patients (P = .032 and P = .012, respectively;
Figure 4D).
Correlation of Bcl-2 and Bax mRNA Expression with
Immunologic Parameters
Finally, we analyzed the correlation between the expression of Bcl-2
and Bax mRNAs and the immunologic parameters of leucocytes de-
rived from HNC patients before receiving any treatments. Data are
shown in Table 1 and Figure 4. Both the percentage of CD3+CD4+
T cells in CD3+ T cells and the absolute number of CD3+CD4+
T cells were statistically significantly correlated with the Bcl-2/Bax ratio
(P = .020 and P = .037, respectively). Additionally, statistically sig-
nificant correlations between NK cell activity and the Bcl-2/Bax ratio
as well as the Bcl-2 expression value (Bcl-2/GAPDH) were observed
(P = .041 and P = .006, respectively).
Discussion
We have previously reported that the combination therapy using
UFT and OK-432 together with radiation has a marked therapeutic
effect in patients with HNC and that OK-432–induced immunity
plays a significant role in the antitumor effect of this combination
therapy through Toll-like receptor 4 (TLR4)/MD-2 [25–27]. It
has been reported that OK-432 elicits antitumor effects by stimulat-
ing immunocompetent cells such as macrophages, T cells, and NK
cells [28,29] and that OK-432 induces interleukin-12 and polarizes
the T cell response to a T helper cell 1 (Th1)–dominant state [30].
Recently, we have demonstrated that OK-432 induces the maturation
Figure 4. Differences of Bcl-2/Bax ratio among the different primary sites were analyzed by Student’s two-tailed t test. Asterisk denotes P<
.05, indicating statistical significance (A). Differences of relationship between Bcl-2/Bax ratio and (B) OS or (C) DFS among the different
primary sites. Differences of Bcl-2/Bax ratio ≥ 1.2 (solid line) versus Bcl-2/Bax ratio < 1.2 (dotted line) were calculated by log-rank test.
Asterisk denotes P < .05, indicating statistical significance. (D) Differences of relationship between Bcl-2/Bax ratio and clinical responses
among the primary sites were analyzed by Student’s two-tailed t test. Asterisk denotes P < .05, indicating statistical significance.
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of dendritic cells, which are dedicated antigen-presenting cells through
TLR4 signaling, and that OK-432–stimulated dendritic cells can in-
duce tumor antigen-specific cytotoxic T lymphocytes in vitro as well
as in vivo [26,31,32]. Therefore, we have applied the combination ther-
apy by using radiation, UFT or S-1, and OK-432 to the patients who
entered the study. Furthermore, in our previous study, we observed a
statistically significant relationship between increased IFN-γ protein
levels in the sera as well as clinical responses in HNC patients admin-
istered OK-432 and expression of TLR4 andMD-2 genes in circulating
immune cells from the patients [26]. Although it was expected that
expression of both TLR4 and MD-2 genes in patient-derived PBMCs
may be a useful biomarker to discriminate between likely responders
and nonresponders to OK-432 as well as to predict the therapeutic
effect of OK-432–based immunotherapy, its utility is so far limited
to patients undergoing OK-432–based immunotherapy. While expres-
sion of TLR4 and MD-2 genes in PBMCs from the patients was not a
prognostic biomarker for numerous cancer patients except for the pa-
tients undergoing OK-432 therapy, these previous data suggested at
least that evaluation of the characteristics of circulating immune cells
derived from cancer patients might have prognostic value.
The findings from the current study suggested that expression ratio
of the genes for antiapoptotic protein Bcl-2 and proapoptotic protein
Bax in circulating immune cells derived from patients with HNC
Figure 5. Correlations between (A) Bcl-2/Bax ratio and percentage of CD4+ T cells, (B) Bcl-2/Bax ratio and absolute number of CD4+
T cells, (C) Bcl-2/Bax ratio and NK activity, (D) Bcl-2 expression value and NK activity, and (E) Bax expression value and NK activity were
quantified by Spearman’s rank correlation coefficient and regression calculation. Asterisk denotes P < .05, which was considered statisti-
cally significant.
Table 1. Correlation between Expression of Bcl-2 and Bax mRNAs and Immunologic Parameters.
Bcl-2/Bax Bcl-2/GAPDH Bax/GAPDH N
P1 r2 P r P r
WBC (per mm3) .662 0.054 .265 0.137 .131 0.185 76
Lymphocyte (%) .691 0.049 .057 0.232 .110 0.196 76
Lymphocyte (per mm3) .681 0.051 .250 0.142 .682 0.051 76
Monocyte (per mm3) .630 0.059 .357 0.113 .091 0.207 76
CD3+ (%) .098 0.236 .240 0.169 .417 0.117 51
CD3+ (per mm3) .181 0.192 .142 0.211 .473 0.104 51
CD3+CD4+/CD3+ (%) .020*3 0.328 .131 0.216 .386 0.125 51
CD3+CD4+ (per mm3) .037*3 0.296 .053 0.275 .410 0.119 51
CD3+CD8+/CD3+ (%) .325 0.142 .233 0.172 .843 0.029 51
CD3+CD8+ (per mm3) .764 0.044 .731 0.050 .664 0.063 51
CD4+/CD8+ ratio .299 0.150 .383 0.126 .675 0.061 51
CD16+ (%) .392 0.131 .978 0.004 .406 0.127 51
CD16+ (per mm3) .526 0.097 .807 0.037 .624 0.075 51
CD57+ (%) .586 0.083 .692 0.061 .353 0.142 51
CD57+ (per mm3) .698 0.059 .595 0.081 .590 0.083 51
NK activity (%) .041*3 0.279 .006*3 0.366 .725 0.049 54
LAK activity (%) .500 0.094 .297 0.145 .351 0.130 54
Pre-LAK activity (%) .337 0.133 .870 0.023 .323 0.137 54
1P values were arrived at using regression calculation.
2r, Spearman’s rank correlation coefficient.
3Asterisk denotes P < .05, indicating statistical significance.
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might have a marked prognostic impact. Enhancing antitumor host
response in cancer patients is critical for improvement of therapeutic
effects and clinical outcomes; thus, it may be a useful prognostic strat-
egy to assess expression of proapoptotic and antiapoptotic genes in
circulating immune cells.
In addition, the comparison of Bcl-2/Bax ratio with TNM classi-
fication in prognostic value for head and neck cancer patients indi-
cates that expression of these genes might detect the prognostic risks
and advantages that could not be detected by TNM classification;
thus, using both expression ratio of Bcl-2/Bax mRNAs and TNM
classification should contribute more strongly to prediction of out-
comes, selection of cases, and establishment of personalized therapy
for individual patients. Furthermore, the results from the study eval-
uating the difference among the different primary sites in Bcl-2/Bax
ratio and in clinical outcome suggested that Bcl-2/Bax ratio may be a
better prognostic biomarker in patients with tongue cancer than in
those with gingival cancer.
IFN-γ, a representative Th1 cytokine, plays an important role in
anticancer immunity. It has been reported that IFN-γ production is
associated with a favorable clinical outcome in patients with several
types of malignancies [33] and that OK-432 augments anticancer
host responses by increasing production of Th1 cytokines, especially
IFN-γ [26]. Actually, the findings in the current experiments have
clearly indicated that the Bcl-2/Bax ratio in the circulating immune
cells was significantly higher in IFN-γ(+) patients than in IFN-γ(−)
patients and also higher in the patients who showed favorable thera-
peutic effect and clinical outcome. It was strongly suggested that the
increase of the apoptosis-associated gene expression might inhibit
IFN-γ production in response to OK-432 and then decreased anti-
cancer effect of the therapy.
The cellular and molecular mechanisms for regulating expression
of Bcl-2 and Bax genes should be elucidated for these genes to be a
more valuable biomarker. Kim et al. reported that expression of the
proapoptotic protein Bax was elevated in peripheral blood CD8+ T
cells from the patient with HNSCC [6], while our data showed that
both the percentage and absolute number of CD4+ T cells but not
CD8+ in peripheral blood were statistically significantly correlated
with the Bcl-2/Bax ratio (Figure 5). In addition, the number of
CD4+ T cells was relatively high in PBMCs, which showed high
Bcl-2 expression values (P = .053, Table 1); thus, we considered that
the Bcl-2/Bax balance was affected by the change of Bcl-2 gene ex-
pression level but not Bax expression in CD4+ T cells. Most of the
patients in the present study received radiation and oral 5-fluorouracil
in combination with OK-432–based immunotherapy. Different
results between our study and the study of Kim et al. may be due
to the difference of the therapies. Further, in the current cases,
NK cell activity was significantly correlated both with the Bcl-2/
Bax ratio and with Bcl-2 expression, whereas the number of NK cells
estimated by CD16+ and CD57+ was not correlated with expression
of these genes. The findings suggest that the balance of expression of
Bcl-2 and Bax genes may have an effect on NK cell activity but not
on cell number.
The markers may be also useful as therapeutic targets. If a cytokine
that can increase the Bcl-2/Bax ratio can be elucidated, a therapy
using the cytokine could be established for patients who show low
levels of that cytokine. Further, anticytokine therapy using a neutral-
izing antibody may have a therapeutic ability for patients with an
elevated level of the serum cytokine that can decrease the Bcl-2/
Bax ratio. Moreover, it has been reported that certain immuno-
therapeutic agents increase antiapoptotic molecules and decrease
proapoptotic molecules in immune cells [34,35], and combination
therapy using the immune adjuvant may have a therapeutic value
for patients with malignancies.
We expect that the ongoing prospective study will elucidate the
expression mechanism for these genes in circulating immune cells
from cancer patients and will establish a biomarker.
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Table W1. Relationship between Expression of Bcl-2 and Bax mRNAs and Sex, Age, and T and
N Stages.
Bcl-2/Bax Bcl-2 Bax
P value
Male versus female .185 .350 .985
Age .866 .744 .806
T1 + T2 versus T3 + T4 .233 .774 .869
N(−) versus N(+) .324 .609 .130
The relationships of Bcl-2/Bax, Bcl-2, and Bax with sex and TN classification were performed using
Student’s two-tailed t test.
Correlations between Bcl-2/Bax, Bcl-2, and Bax and age were examined by Spearman’s rank cor-
relation coefficient and regression calculation.
